Sugi Predict

Sugi Predict / Targets / CACNG7

CACNG7

Voltage-dependent calcium channel gamma-7 sub · P62955 · CACNG7 on Sugi Atlas →

6,596 patent compounds predicted against CACNG7, 2,853 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20
SCHEMBL3248439 SCHEMBL3248439 0.45 5/20

Clinical trials — most relevant to CACNG7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain PHASE4RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Pain and Chronic Pancreatitis - Clinical End Experimental Studies PHASE2/PHASE3COMPLETED
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study PHASE3COMPLETED
Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain PHASE3COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients PHASE2UNKNOWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Peripheral KV7 Activation for Pain Relief EARLY_PHASE1COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 EARLY_PHASE1COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Pre-Emptive Analgesia in Ano-Rectal Surgery nanCOMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Cenobamate Expanded Access Program (EAP) nanAPPROVED_FOR_MARKETING
Pregabalin Phonophoresis and MET for Knee Osteoarthritis nanRECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
ST-segment Elevation as an AF Endophenotype nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNG7 binder may also engage these)

ProteinNameSimilarity
P62956 — 1.000 P62956 →
P62957 — 1.000 P62957 →
Q8VHW4 — 0.990 Q8VHW4 →
Q8VHW8 — 0.988 Q8VHW8 →
CACNG5 Voltage-dependent calcium channel gamma-5 sub 0.985 landscape →
Q7Z7J7 — 0.975 Q7Z7J7 →
H3BS89 — 0.970 H3BS89 →
Q7TSY2 — 0.969 Q7TSY2 →
Q1L8F4 — 0.966 Q1L8F4 →
Q5U4E0 — 0.965 Q5U4E0 →
Q17R16 — 0.962 Q17R16 →
Q3KRC4 — 0.947 Q3KRC4 →
Q8BHH9 — 0.945 Q8BHH9 →
Q86UP9 — 0.945 Q86UP9 →
Q9Y693 — 0.944 Q9Y693 →
Q8K3J9 — 0.942 Q8K3J9 →
Q9NQ84 — 0.942 Q9NQ84 →
Q6ZVK1 — 0.942 Q6ZVK1 →
Q4R4I5 — 0.940 Q4R4I5 →
Q4R6E8 — 0.939 Q4R6E8 →
Q8BM86 — 0.939 Q8BM86 →
Q71SV0 — 0.939 Q71SV0 →
Q15012 — 0.939 Q15012 →
Q5RAH0 — 0.938 Q5RAH0 →
Q6QRN8 — 0.937 Q6QRN8 →
Q6P501 — 0.936 Q6P501 →
Q5E9L0 — 0.936 Q5E9L0 →
Q91XQ6 — 0.936 Q91XQ6 →
Q13635 — 0.935 Q13635 →
Q5ZML7 — 0.935 Q5ZML7 →